Firm News

The Latest News from Lucosky Brookman

Lucosky Brookman is a leader in the representation of small and micro-cap companies. The Firm has led it clients through numerous capital raise transaction and over a dozen uplisting and initial public offering transactions.  Access the latest news about Lucosky Brookman, our clients’ business transactions and industry updates here. 

Lucosky Brookman LLP Acts as Company Counsel to Buda Juice, Inc. in $20 Million Initial Public Offering

Lucosky Brookman LLP Acts as Company Counsel to Buda Juice, Inc. in $20 Million Initial Public Offering

Buda Juice, Inc. (NYSE American: BUDA), a pioneer of the UltraFresh™ juice category for the supermarket fresh produce department, announced…

Read More
Lucosky Brookman LLP Acts as Placement Agent Counsel to Univest Securities in Globavend Holdings Limited $1.4 Million Registered Direct Offering

Lucosky Brookman LLP Acts as Placement Agent Counsel to Univest Securities in Globavend Holdings Limited $1.4 Million Registered Direct Offering

Globavend Holdings Limited (Nasdaq: GVH), an emerging e-commerce logistics provider offering end-to-end cross-border logistics solutions,…

Read More
Lucosky Brookman LLP Acts as Counsel to EF Hutton in iSpecimen Inc. $5.5 Million Private Placement

Lucosky Brookman LLP Acts as Counsel to EF Hutton in iSpecimen Inc. $5.5 Million Private Placement

iSpecimen Inc. (Nasdaq: ISPC), an online global marketplace connecting scientists with healthcare specimen providers for medical research,…

Read More
Lucosky Brookman LLP Acts as Issuer Counsel to Tron Inc. in $18 Million Strategic Equity Investment

Lucosky Brookman LLP Acts as Issuer Counsel to Tron Inc. in $18 Million Strategic Equity Investment

Tron Inc. (Nasdaq: TRON), a publicly traded innovation company focused on blockchain and digital assets, announced the completion of an $18…

Read More
Lucosky Brookman LLP Acts as Company Counsel to Stardust Power on $15 Million Senior Secured Convertible Debt Facility

Lucosky Brookman LLP Acts as Company Counsel to Stardust Power on $15 Million Senior Secured Convertible Debt Facility

Stardust Power Inc. (NASDAQ: SDST), an American developer of battery-grade lithium carbonate, announced that it has executed a Securities…

Read More
Lucosky Brookman LLP Acts as Company Counsel to AiRWA Inc. on $15.7 Million Registered Direct Offering

Lucosky Brookman LLP Acts as Company Counsel to AiRWA Inc. on $15.7 Million Registered Direct Offering

AiRWA Inc. (Nasdaq: YYAI), a technology licensing company developing a next-generation RWA-focused exchange for the trading of tokenized…

Read More
Lucosky Brookman LLP Acts as Company Counsel to Mangoceuticals, Inc. on $2.5 Million Registered Direct and Concurrent Private Placement Offering

Lucosky Brookman LLP Acts as Company Counsel to Mangoceuticals, Inc. on $2.5 Million Registered Direct and Concurrent Private Placement Offering

Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling health and wellness products via secure…

Read More
Lucosky Brookman LLP Acts as Counsel to Joseph Gunnar on Republic Technologies’ $10 Million First Drawdown of Convertible Note Facility

Lucosky Brookman LLP Acts as Counsel to Joseph Gunnar on Republic Technologies’ $10 Million First Drawdown of Convertible Note Facility

Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (OTCQB: DOCKF), a publicly traded technology company integrating…

Read More
Lucosky Brookman LLP Acts as Company Counsel to E-Home Household Service Holdings Limited in $13.5 Million Registered Direct Offering

Lucosky Brookman LLP Acts as Company Counsel to E-Home Household Service Holdings Limited in $13.5 Million Registered Direct Offering

E-Home Household Service Holdings Limited (“E-Home” or the “Company”) successfully completed a registered direct offering of…

Read More
Lucosky Brookman LLP Acts as Counsel to Konik Capital Partners on Closed $50 Million PIPE Financing for Kazia Therapeutics

Lucosky Brookman LLP Acts as Counsel to Konik Capital Partners on Closed $50 Million PIPE Financing for Kazia Therapeutics

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company based in Sydney, Australia, announced the successful…

Read More